Paper published (16 Feb 2022) by Dept. of Health #Australia about utilisation of antimicrobials used to treat bacterial pneumonia in principal referral hospitals during the COVID-19 pandemic in 2020 beg some serious question.
The paper mentions:-
"Overall usage (in 2020) of doxycycline, azithromycin, amoxicillin and cefuroxime decreased in principal referral hospitals compared to 2019." in #Australia
Please note, to treat bacterial pneumonia, you need doxycycline or azithromycin.
Antibacterials usage to treat community-acquired pneumonia in 2020 was not same as 2019
"In the non-critical-care setting, usage of oral amoxicillin and of oral azithromycin for the July to December period fell, on average, by 21.1% and 23.7% respectively between 2019 and 2020."
The paper mentions that data submitted to National Antimicrobial Utilisation Surveillance Program (NAUSP) in #Australia reflects dispensing and/or distribution, not actual consumption.
Hospitals were perhaps stocking up (Mar/April 2020) anticipating demand.
Paper also mentions that pandemic related interventions may have unintended benefits on non SARS-CoV-2 infections rates such as community-acquired pneumonia (CAP) - Can this be true?
Lab confirmed influenza was 8 times lower that the five-year avg.
A different report published by Dept. of Health #Australia about Antimicrobial use in Australian Hospitals during 2020 compared to 2019 which mentions that the total annual use of the macrolides (including azithromycin) fell across Australia (15.5% decline).
A very interesting entry in the report:-
"The reduction in hospital usage of antibacterials commonly used to treat community-acquired pneumonia, such as doxycycline and azithromycin, may be due to a reduction in the number of pneumonia cases in 2020."
So, if Lab confirmed influenza was all time low AND there was reduction in community-acquired pneumonia (CAP) then what happened in 2020 in #Australia ? What caused so many deaths?
National Centre for Immunisation Research and Surveillance (NCIRS) #Australia:-
24th Sept 2021-
COVID-19 vaccines do reduce onward transmission of SARS-CoV-2 to a degree.
28th Feb 2023-
Not as effective in preventing transmission | they were not designed to reduce transmission
"Like most vaccines, they were not designed to reduce transmission." - That's a Damn lie.
COVID-19 vaccines were "provisionally" approved by the TGA (#Australia ) to prevent and/or active immunissation against COVID-19 and it clearly doesn't do that.
In recent COVID-19 vaccine report, TGA #Australia has advised that they have updated the Product Information leaflet for "Heavy menstrual bleeding" as an adverse reaction for COVID-19 mRNA vaccines.
Also advised to see Dr. for any new vaginal bleeding after menopause.
They have advised that although a definitive link has not been established, the TGA considers there is a possibility that heavy periods could be causally associated with vaccination.
To 13 Feb 2023, TGA DAEN is reporting 926 cases of Heavy menstrual bleeding post mRNA COVID-19 vaccination i.e - Moderna and/or Pfizer (Medicine suspected).
Is the Department of Health and Aged care, The TGA and ATAGI telling #Australian's the true picture of rise in Myocarditis (and it's seriousness) cases in #Australia post Covid-19 mRNA vaccines?
Like many (including myself), before mid-2021 (and certainly not in 2020) heard of Myocarditis (A rare heart disease). However, Mid 2021 this "rare" heart disease was not rare anymore.
In the #COVID19 Vaccine safety report published on 27th May 2021, TGA #Australia for the first time mentioned that they were investigating small number of Australian cases for Myocarditis and Pericarditis following #Pfizer vaccine.
Australian Technical Advisory Group on Immunisation (ATAGI) announced on 8th Feb 2023 of #Pfizer Bivalent vaccine for use as a booster COVID-19 vaccine in people aged 12 years and older in #Australia
No immunogencity data available for 12 - 18 yrs of age group yet this #Pfizer bivalent #COVID19 vaccine is "provisionally" approved in #Australia for use as a booster COVID-19 vaccine in people aged 12 years and older.